Selank
MetabolicMetabolic-medicine specialists evaluate Selank against glycemic control, insulin sensitivity, visceral adiposity, and the broader cardiometabolic risk profile. Modulates GABA-A receptor systems indirectly Increases serotonin metabolism via enkephalinase inhibition. Influences IL-6, BDNF, and TNF-α. The result is anxiolysis without the sedation, dependence, or motor impairment of benzodiazepines.. Baseline labs (HbA1c, fasting glucose, fasting insulin, HOMA-IR, lipid panel, ALT/AST, hsCRP) with 6-8 week follow-up on the 300 mcg per spray; 2-3 sprays daily daily for 2-4 week courses protocol provide the clinical evaluation framework.
Key Takeaways
Metabolic lens: Selank is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers. Mechanism: Modulates GABA-A receptor systems indirectly. Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle. Metabolic dose: 300 mcg per spray; 2-3 sprays daily daily for 2-4 week courses via intranasal/subq. Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.
Modulates GABA-A receptor systems indirectly. Increases serotonin metabolism via enkephalinase inhibition. Influences IL-6, BDNF, and TNF-α. The result is anxiolysis without the sedation, dependence, or motor impairment of benzodiazepines. Metabolic implications: how the mechanism interacts with insulin signalling, AMPK and mitochondrial biogenesis, visceral adiposity, and the appetite circuit. Selank's contribution at each layer is examined in the subsections below, with reference to the clinical biomarkers (HbA1c, fasting insulin, HOMA-IR, hsCRP, ALT/AST) that track each.
Insulin signalling and glycemic effect
Selank's relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.
AMPK and mitochondrial signalling
Independent of insulin-receptor pharmacology, several peptides in this category engage AMPK and mitochondrial biogenesis pathways. Selank engages this layer indirectly through its effect on adiposity, inflammation, and the broader metabolic milieu. The practical effect is sustained shifts in fasting insulin, fasting glucose, and energy expenditure that are not visible in single-meal glycemic curves but accumulate across a cycle.
Visceral fat and the cardiometabolic axis
Selank's effect on visceral adipose tissue, hepatic steatosis, and cardiometabolic risk indices is the dimension most clinically tracked. Visceral adipose effects emerge gradually over months of consistent dosing rather than acutely. The most-tracked markers are waist circumference, ALT/AST (hepatic), hsCRP (inflammation), and — where available — DEXA-quantified visceral fat.
Where Selank is used for weight management, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.
Selank for lipid profile is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.
In the metabolic syndrome population, Selank for insulin sensitivity produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
Where Selank is used for glp-1 synergy, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | Intranasal | 300 mcg per spray; 2-3 sprays daily | 8–12 weeks on / 4 weeks off |
| Conservative starter | Intranasal | 180 mcg per spray; 2-3 sprays daily | 4–6 weeks initial cycle |
| Metabolic focus | Intranasal | 300 mcg per spray; 2-3 sprays daily | Daily for 2-4 week courses |
| Maintenance phase | Intranasal | 210 mcg per spray; 2-3 sprays daily | Ongoing with periodic pauses |
Dose timing for Selank is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Selank stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.
- Selank + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with Selank's mechanism in metabolic / endocrine protocols.
- Selank + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with Selank's mechanism in metabolic / endocrine protocols.
- Selank + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with Selank's mechanism in metabolic / endocrine protocols.
- Selank + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with Selank's mechanism in metabolic / endocrine protocols.
Excellent. No reported dependence. Mild nasal irritation possible.
Lens-specific safety considerations for metabolic / endocrine use of Selank: Excellent. No reported dependence. Mild nasal irritation possible. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | Metabolic |
| Semaglutide (GLP-1) | GLP-1 receptor agonist | ~7 days | The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding |
| Cagrilintide | Long-acting amylin analogue | ~7 days | A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone |
| Tesamorelin | Stabilised GHRH analogue | ~30 min | An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction |
What metabolic labs should I track?
Will I regain weight after stopping Selank?
Will Selank affect my muscle mass during weight loss?
Pancreatitis or thyroid risk?
How long until I see results from Selank?
What is Selank?
Start a Selank Protocol
Alukard provides physician-supervised metabolic protocols with GMP-certified Selank and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
Get ProtocolQuick Facts
- Molecular weight
- 751 Da
- Sequence length
- 7 aa
- Half-life
- CNS effect lasts hours; plasma short
- WADA
- Not on prohibited list
- FDA
- Unapproved (approved in Russia)
- Research
- Russian clinical trials in GAD
Stack Partners
All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Selank unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Metabolic / Endocrine Protocol for Selank
Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
HIPAA Compliant · GMP Certified · Physician Supervised